ERBB2 and gastric cancer: Cohort G of the TranStar102 trial was designed to evaluate osemitamab in combination with CAPOX and nivolumab as first-line treatment for patients with HER2-negative or unknown advanced or metastatic GC/GEJC, regardless of CLDN18.2 and PD-L1 status.